Telapristone (INNTooltip International Nonproprietary Name), as telapristone acetate (proposed brand names Proellex, Progenta; former code name CDB-4124), is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids.

[1][2] It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications.

[1] In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity.

This article about a steroid is a stub.

You can help Wikipedia by expanding it.This drug article relating to the genito-urinary system is a stub.